REducing AntiPsychotic use in residential care: Huntington Disease. A pilot Randomised Controlled Trial

Not Applicable

Completed

• Conditions: Huntington Disease; Antipsychotic use; Neurological - Neurodegenerative diseases; Human Genetics and Inherited Disorders - Other human genetics and inherited disorders; Public Health - Health service research

• Registration Number: ACTRN12614000083695
• Lead Sponsor: Huntington Disease Service, Westmead Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-01-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

1.Male or Female 18 years or older
2.Clinical HD, and a confirmatory family history OR >= 36 CAG repeats upon genetic testing
3.Living in RCF in NSW- including group homes with 24-hour supervision, hostels and nursing homes
4.Currently receiving a stable dose of regular antipsychotic medications for management of behavioural symptoms, for at least 4 months prior to enrolment (see exclusion criteria).
5.Able to provide informed consent, or have a suitable senior person responsible who is able to provide informed consent.

Exclusion Criteria

1.Change of antipsychotic dose within 4 months prior to enrolment
2.Psychotic symptoms (new hallucinations or delusions) within 1 year of enrolment
3.People taking anti-psychotic medications solely for control of chorea
4.Other unstable medical or psychiatric illness, making it unsafe to reduce anti-psychotic dose

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of people with HD who has had a reduction in antipsychotic dosage at 4 months, in RCF receiving MFI vs. SSE. Dosage will be assessed as per medication chart, including all regular and prn doses for 1 week prior to each time-point. Any change in antipsychotic type will be managed by calculating dose equivalence.[At 4 months post intervention<br>]

Secondary Outcome Measures

Name	Time	Method
Changes in the severity of behavioural symptoms, as measured by the Neuropsychiatric Inventory-Q (NPI-Q).[At 4 months post intervention];Proportion of people with HD who has had a reduction in antipsychotic dosage at 4 months for each strategy, compared to 4 months prior to enrolment. This secondary outcome takes a 'before and after' analysis approach, often used in health services research. It incorporates all three time points- 4 months pre enrolment, at enrolment, and 4-months post enrolment.[At 4 months post intervention]